A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV.
Miglietta F, et al. Among authors: gaudio m.
Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480.
Clin Cancer Res. 2023.
PMID: 37417941
Free PMC article.